Regular Aspirin Use May Lower Breast Cancer Risk

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 12
Volume 4
Issue 12

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirin or ibuprofen) regularly for 5 years or more had a 40% lower risk of breast cancer than those who did not report such use, Dr. Randall E. Harris and his colleagues at the Ohio State University Comprehensive Cancer Center have found.

COLUMBUS, Ohio--Women who said they used an NSAID (usually aspirinor ibuprofen) regularly for 5 years or more had a 40% lower riskof breast cancer than those who did not report such use, Dr. RandallE. Harris and his colleagues at the Ohio State University ComprehensiveCancer Center have found.

This case-control study involved 303 breast cancer patients diagnosedat the University's Arthur G. James Cancer Hospital and 906 controls(women who underwent screening mam-mography and had no detectablebreast disease). Risk factor data were collected by personal interviewsat the time of diagnosis or screening.

Significantly more women in the control group (27%) reported regularNSAID use than did the breast cancer patients (19%). Calculationof odds ratios showed a reduction in risk of 36% for those whotook NSAIDs three or more times a week for 6 months or more, anda reduction of 40% among those who used NSAIDs seven times a weekfor 5 years or more.

These results, published in Oncology Reports (2:591-592, 1995),are supported by an earlier study by Dr. Harris' team that matched744 newly diagnosed breast cancer patients with 767 controls drawnfrom hospital patients with medical conditions unrelated to breastcancer.

That study found a 37% reduction in breast cancer risk among womenwho reported using NSAIDs at least three times a week for at least5 years (Prev Med 24:119-120, 1995).

Related Videos
More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.
Administering immunotherapy following surgery in patients with early-stage triple-negative breast cancer does not appear to be as effective as beginning with neoadjuvant treatment, says Peter Schmid, MD, PhD.
Heather A. Parsons, MD, MPH, says she is excited about HER2 as a biomarker and investigating the biology of metastatic breast cancer with a minimally invasive liquid biopsy platform.
Exercise and healthy lifestyles can lower the risk of cancer or the symptoms of cancer treatment despite having genetic dispositions, said Neil M. Iyengar, MD.
The Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital includes a social worker, nurse practitioners, a medical oncologist, a radiation oncologist, and surgeons, says Claudia Tellez, MD.
The goal of creating the Hispanic Breast Cancer Clinic at Northwestern Memorial Hospital is to establish a safe space for Hispanic patients, says Claudia Tellez, MD.
Several factors may contribute to the low Hispanic breast cancer population at Northwestern Memorial Hospital, including a lack of resources and a focus on other disease types.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Related Content